PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24683044-7 2014 Modulation by metformin of 42 of 1281 pulmonary microRNAs in smoke-free mice highlighted a variety of mechanisms, including modulation of AMPK, stress response, inflammation, NFkappaB, Tlr9, Tgf, p53, cell cycle, apoptosis, antioxidant pathways, Ras, Myc, Dicer, angiogenesis, stem cell recruitment, and angiogenesis. Metformin 14-23 transformation related protein 53, pseudogene Mus musculus 196-199 24372553-9 2014 Treatment with metformin attenuated the HG-induced reduction of SIRT1 expression, modulated the SIRT1 downstream targets FoxO-1 and p53/p21, and protected endothelial cells from HG-induced premature senescence. Metformin 15-24 transformation related protein 53, pseudogene Mus musculus 132-135 23228442-3 2013 Metformin has also been reported to inhibit mTORC1 independent of AMPK through p53-dependent regulated in development and DNA damage responses 1 (REDD1) or by inhibiting Rag GTPases. Metformin 0-9 transformation related protein 53, pseudogene Mus musculus 79-82 23741061-0 2013 Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Metformin 0-9 transformation related protein 53, pseudogene Mus musculus 70-73 22378745-7 2012 The decrease in p53 abundance caused by metformin was abolished by inhibition of murine double minute 2 (MDM2), a ubiquitin ligase that mediates p53 degradation, as well as by overexpression of a dominant-negative AMPK or a shRNA-mediated knockdown of SIRT1. Metformin 40-49 transformation related protein 53, pseudogene Mus musculus 16-19 22378745-7 2012 The decrease in p53 abundance caused by metformin was abolished by inhibition of murine double minute 2 (MDM2), a ubiquitin ligase that mediates p53 degradation, as well as by overexpression of a dominant-negative AMPK or a shRNA-mediated knockdown of SIRT1. Metformin 40-49 transformation related protein 53, pseudogene Mus musculus 145-148 21806981-10 2011 These data suggest that anti-melanoma effects of metformin are mediated through p21- and AMPK-independent cell cycle arrest, apoptosis and autophagy associated with p53/Bcl-2 modulation, mitochondrial damage and oxidative stress. Metformin 49-58 transformation related protein 53, pseudogene Mus musculus 165-168 29340030-5 2017 In the K18-gT121+/-; p53fl/fl; Brca1fl/fl (KpB) mouse model, metformin inhibited tumor growth in both lean and obese mice. Metformin 61-70 transformation related protein 53, pseudogene Mus musculus 21-24 34506671-5 2022 In presence of metformin in the resistant induction process to DTIC, (MET-DTIC) cells had increased antioxidant thiols, MDA, nuclear p53, 8-OH-DG, Nrf2 and reducing NF-kB, weakening the DTIC-resistant phenotype. Metformin 15-24 transformation related protein 53, pseudogene Mus musculus 133-136 31645006-8 2019 Metformin treatment induced AMPK-dependent alleviation of dyslipidemia in a dose and time dependent manner, upregulated p53 (Ser-15), restored tissue architecture and reduced oxidative stress in tissues of AEBN and arecoline treated mice. Metformin 0-9 transformation related protein 53, pseudogene Mus musculus 120-123 33543290-9 2021 In in-vitro granulosa cell experiments, the anti-apoptotic effect of metformin was blocked after inhibiting p53 or p21 function, and the expression of p53 mRNA was blocked with AMPK inhibitor, suggesting that the anti-apoptotic effect was AMPK/p53/p21-mediated. Metformin 69-78 transformation related protein 53, pseudogene Mus musculus 108-111 26784190-0 2016 Metformin Restores Parkin-Mediated Mitophagy, Suppressed by Cytosolic p53. Metformin 0-9 transformation related protein 53, pseudogene Mus musculus 70-73 28533436-8 2017 Blocking the axis using corresponding kinase inhibitors or neutralizing antibodies against different SASP components sensitized the cotreatment effect of metformin and ABT-263 in p53-WT cancer cells. Metformin 154-163 transformation related protein 53, pseudogene Mus musculus 179-182 28533436-9 2017 The in vivo experiments showed that metformin and ABT-263 synergistically inhibited the growth of p53-defective (but not p53-WT) cancer cells in tumor xenograft nude mice. Metformin 36-45 transformation related protein 53, pseudogene Mus musculus 98-101 28533436-10 2017 These results suggest that the combination of metformin and ABT-263 may be a novel targeted therapeutic strategy for p53-defective cancers. Metformin 46-55 transformation related protein 53, pseudogene Mus musculus 117-120 28281393-7 2017 CONCLUSION: Metformin effects on tumor cells measured under in vitro conditions may differ from those determined in vivo due to p53 and heterogeneous environmental factors. Metformin 12-21 transformation related protein 53, pseudogene Mus musculus 128-131 28533436-0 2017 Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells. Metformin 0-9 transformation related protein 53, pseudogene Mus musculus 93-96 28533436-4 2017 However, it remains unknown whether mTORC1 activation confers ABT-263 resistance and whether metformin can overcome it in the p53-defective contexts. Metformin 93-102 transformation related protein 53, pseudogene Mus musculus 126-129 28533436-5 2017 In this study, we for the first time demonstrated that metformin and ABT-263 synergistically elicited remarkable apoptosis through orchestrating the proapoptotic machineries in various p53-defective cancer cells. Metformin 55-64 transformation related protein 53, pseudogene Mus musculus 185-188 28459206-8 2017 The anti-tumorigenic effect of metformin was mediated by enhancement of adenosine monophosphate protein kinase activity and elevation of P53 protein as well as the suppression of nuclear factor-kappa B, DNA contents, and cyclin D1 gene expression. Metformin 31-40 transformation related protein 53, pseudogene Mus musculus 137-140 28242651-11 2017 Furthermore, metformin induced p53 and NF erythroid-2-related factor-2 activity in splenic CD4+ T cells. Metformin 13-22 transformation related protein 53, pseudogene Mus musculus 31-34 26784190-9 2016 However, metformin decreased ER stress and p53 expression, resulting in induction of Parkin-mediated mitophagy. Metformin 9-18 transformation related protein 53, pseudogene Mus musculus 43-46 26784190-11 2016 Taken together, these results indicate that metformin treatment facilitates Parkin-mediated mitophagy rather than mitochondrial spheroid formation by decreasing the inhibitory interaction with cytosolic p53 and increasing degradation of mitofusins. Metformin 44-53 transformation related protein 53, pseudogene Mus musculus 203-206